Neumora Therapeutics Inc NMRA.OQ NMRA.O is expected to show no change in quarterly revenue when it reports results on November 3 (estimated) for the period ending September 30 2025
LSEG's mean analyst estimate for Neumora Therapeutics Inc is for a loss of 33 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 3 "hold" and 1 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Neumora Therapeutics Inc is $6.50, about 54.9% above its last closing price of $2.93
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -0.36 | -0.37 | -0.33 | Beat | 10.4 |
Mar. 31 2025 | -0.35 | -0.37 | -0.42 | Missed | -12.2 |
Dec. 31 2024 | -0.46 | -0.45 | -0.37 | Beat | 17.1 |
Sep. 30 2024 | -0.38 | -0.39 | -0.45 | Missed | -15.4 |
Jun. 30 2024 | -0.38 | -0.37 | -0.37 | Met | 0.4 |
Mar. 31 2024 | -0.34 | -0.34 | -0.34 | Met | 0.6 |
Dec. 31 2023 | -0.73 | -0.55 | -0.71 | Missed | -29.1 |
Sep. 30 2023 | -0.36 | -0.36 | -1.14 | Missed | -214.5 |
This summary was machine generated October 31 at 22:32 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments